Clinical Trial Update: Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the pharmacokinetic impact of boosted tipranavir/ritonavir on a triple-drug nucleoside and non-nucleoside reverse transcriptase inhib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ritonavir (Ritonavir)
• Tipranavir (tipranavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED